Surmodics, Inc. (NASDAQ:SRDX - Get Free Report) CFO Timothy J. Arens sold 7,009 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the sale, the chief financial officer now owns 70,350 shares in the company, valued at $2,774,604. The trade was a 9.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Surmodics Price Performance
NASDAQ:SRDX opened at $39.54 on Thursday. The stock has a market capitalization of $566.61 million, a PE ratio of -48.81 and a beta of 1.20. Surmodics, Inc. has a 1-year low of $25.17 and a 1-year high of $42.44. The firm has a fifty day simple moving average of $38.50 and a 200 day simple moving average of $39.58. The company has a current ratio of 3.96, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25.
Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.14. The company had revenue of $33.23 million during the quarter, compared to the consensus estimate of $30.69 million. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%. On average, research analysts expect that Surmodics, Inc. will post 0.17 EPS for the current fiscal year.
Hedge Funds Weigh In On Surmodics
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing | Ad
Starting with what I call Exec. Order 001.
It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...
I put all the details together for you here — but please hurry.
A number of institutional investors have recently bought and sold shares of the business. Quest Partners LLC boosted its stake in shares of Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company's stock worth $42,000 after acquiring an additional 1,071 shares during the period. Longfellow Investment Management Co. LLC acquired a new position in shares of Surmodics in the third quarter valued at $67,000. Lazard Asset Management LLC raised its position in shares of Surmodics by 13.4% in the first quarter. Lazard Asset Management LLC now owns 5,679 shares of the company's stock valued at $166,000 after purchasing an additional 673 shares during the period. Hardin Capital Partners LLC acquired a new stake in shares of Surmodics during the 2nd quarter worth about $206,000. Finally, SG Americas Securities LLC bought a new stake in shares of Surmodics during the 3rd quarter worth about $220,000. Institutional investors and hedge funds own 96.63% of the company's stock.
Wall Street Analysts Forecast Growth
SRDX has been the topic of a number of research reports. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a research report on Thursday, November 7th. StockNews.com started coverage on shares of Surmodics in a research note on Saturday, November 23rd. They set a "hold" rating for the company. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Surmodics presently has a consensus rating of "Hold" and an average target price of $50.00.
View Our Latest Analysis on SRDX
Surmodics Company Profile
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
